Reaction Biology, founded in 2001 and headquartered in Malvern, PA with 50+ employees, is a CRO providing early drug discovery services to pharma and academic / research customers. It specializes in biochemical (i.e. kinase and epigenetic) and cell-based assay services and is expanding into biophysical and ion channel screening services. The company’s primary source of revenue is its kinase assay services – these are built around Reaction’s Kinase HotSpot radioisotope platform, which eliminates the risk of bad data generally found in other detection formats. Further, Reaction is competitively priced with minimal margin impact because of its proprietary workflow management software which streamlines the lab workflow. The company offers 650+ kinase assays, 235+ epigenetic assays, and 300+ epigenetic proteins, and has served 1,100+ customers historically including approximately 500 in 2018. As of Q3 2019, revenues are up 47% and they are solidly profitable.
